Health
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.1 ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.2
About this update from Johnson & Johnson
[{"type":"text","content":"Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill","length":168,"tagName":"p"},{"type":"text","content":"ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treatment","length":172,"tagName":"p"},{"type":"text","content":"SPRING HOUSE, Pa., March 18, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.1 ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.2","length":535,"tagName":"p"},{"type":"text","content":""ICOTYDE delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once–daily pill, making it an easy addition to a patient's routine," said Linda Stein Gold, M.D., Director of Dermatology Clinical Research at Henry Ford Health.a "With new guidance from the International Psoriasis Council that clarifies when to move beyond cycling on topical treatments to systemic therapy, an innovative option like ICOTYDE is a potential game–changer for many adult and adolescent patients."","length":557,"tagName":"p"},{"type":"text","content":"Experience the interactive multimedia news release here: https://www.multivu.com/johnson-johnson/9378651-en-icotyde-icotrokinra-fda-approval-first-line-systemic-treatment-plaque-psoriasis","length":187,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":37,"url":"https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jIgvao1bUyQtFqwMNBmckA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2c...